Liquidia Corporation (LQDA)

Market Cap	901.38M
Revenue (ttm)	15.61M
Net Income (ttm)	-119.48M
Shares Out	84.64M
EPS (ttm)	-1.62
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,029,301
Open	10.15
Previous Close	10.15
Day's Range	10.02 - 10.73
52-Week Range	6.69 - 16.99
Beta	0.20
Analysts	Strong Buy
Price Target	27.14 (+154.84%)
Earnings Date	Nov 13, 2024

About LQDA

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement w...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 26, 2018
• Employees: 145
• Stock Exchange: NASDAQ
• Ticker Symbol: LQDA
• Website: https://www.liquidia.com

Financial Performance

In 2023, Liquidia's revenue was $17.49 million, an increase of 9.75% compared to the previous year's $15.94 million. Losses were -$78.50 million, 91.4% more than in 2022.

Analyst Forecast

According to 8 analysts, the average rating for LQDA stock is "Strong Buy." The 12-month stock price forecast is $27.14, which is an increase of 154.84% from the latest price.

Price Target

$27.14

(154.84% upside)

Analyst Consensus: Strong Buy